STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	May 31, 2016	May 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (369,953)	$ (624,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	171	171
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph. D.	333,437	555,263
Changes in operating assets and liabilities
Accounts payable	(18,153)	(18,370)
Accrued liabilities	(23,538)	8,878
NET CASH USED IN OPERATING ACTIVITIES	(78,036)	(78,583)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	75,592	76,783
NET CASH PROVIDED BY FINANCING ACTIVITIES	75,592	76,783
NET DECREASE IN CASH	(2,444)	(1,800)
CASH AT BEGINNING OF YEAR	3,303	2,280
CASH AT END OF YEAR	$ 859	$ 480